ForJustice monitors 22+ real-time intelligence sources — from FDA adverse events to federal dockets to PubMed studies — to surface emerging litigation opportunities months before the first complaint is filed.
Three stages of intelligence refinement transform scattered signals across federal databases, court systems, and research journals into decisive litigation strategy.
22 autonomous agents continuously monitor FDA adverse events, PubMed studies, federal dockets, regulatory actions, news, and social signals — harvesting raw intelligence around the clock.
AI clusters related signals, scores viability across six dimensions, detects novel patterns no one else is tracking, and filters known mass torts to surface only what’s genuinely new.
Court-ready case briefs with executive summaries, evidence reels, case economics, competitive landscape, jurisdiction analysis, and specific next steps with real deadlines.
Every source that matters, monitored continuously. No signal escapes.
FAERS and MAUDE databases. Drug and device adverse event reports with temporal windowing.
PubMed studies, clinical trials, and seeded random discovery searches for emerging science.
Federal and state filings, docket intelligence, MDL tracking, and specialized matter extraction.
FDA recalls, warning letters, Federal Register rulemakings, and ERISA enforcement.
DOJ, FTC, SEC, EPA press releases. Federal and state attorney general actions and investigations.
Multi-source news monitoring: general, business, and specialized legal news from NLR, JDSupra, ALM.
Reddit consumer complaints, community reports, and grassroots adverse reaction patterns.
Drug metadata, people extraction, SEC EDGAR filings, and web search for emerging signals.
ForJustice doesn't wait for you to ask the right question. It finds the answers you didn't know to look for.
The crown jewel. ForJustice doesn't just track known mass torts — it discovers litigation opportunities that don't exist yet.
Every emerging cluster is scored across causal evidence, exposed population, defendant viability, regulatory corroboration, litigation momentum, and market timing.
Automated 15-section briefs with executive summaries, Bradford Hill analysis, case economics, jurisdiction strategy, and plaintiff acquisition playbooks.
A single FDA report is noise. When PubMed, court filings, and Reddit consumers all converge on the same substance — that's a signal worth millions.
From the first whisper of an adverse event through MDL formation to settlement. Track every litigation opportunity through its complete lifecycle.
Know which firms are moving on an opportunity. Detect law firm activity, intake saturation, lead counsel appointments, and plaintiff steering committee formation.
“The firms that win the largest settlements aren’t the ones who react fastest — they’re the ones who see it first. ForJustice turns intelligence into timing advantage.”
The difference between reacting to litigation and predicting it.
Real analysis from the LEWS pipeline — FAERS data, MDL tracking, consumer signals, and emerging litigation opportunities. No fluff, just signals.
A data-driven overview of every active MDL — where the action is, what’s growing, and where the next opportunities lie. Powered by LEWS: 81,650 clusters tracked, 173 scored.
18,500+ LEWS signals, FAERS death reports, and MDL 3094 stats. The weight loss drug revolution has a dark side — and the legal system is catching up fast.
A second, potentially more devastating wave — MDL 3163 for NAION (sudden vision loss). JAMA study data, settlement projections, and why this may surpass gastroparesis.
Before the lawsuits, before the MDLs, before the attorney ads — there were Reddit posts. How LEWS consumer signal monitoring spotted the wave months early.
The FDA’s FAERS database is publicly available, frequently underutilized by plaintiff firms, and full of litigation-ready intelligence. Here’s what 547 signals reveal.
Tirzepatide has zero reported gastroparesis cases in FAERS — the injury at the center of 75% of GLP-1 lawsuits. Drug-specific data that changes litigation strategy.
The headlines focus on stomach paralysis and vision loss. But a quieter — and potentially massive — category is emerging: psychiatric and neurological adverse events.
The “forever chemicals” mass tort has produced $13B in water utility settlements. But the biggest opportunity — individual injury claims — is still untouched. 15K pending cases.
Three failed bankruptcy gambits, $1.5B in trial verdicts, and 67,000 cases heading to court. MDL tracking data reveals what comes next for the talc litigation.
The firms that identified Roundup risk in 2015, PFAS in 2016, or GLP-1 gastroparesis in 2023 got better cases, cheaper acquisition, and MDL leadership. Here’s how.
Join the firms that will see it first. ForJustice is currently in private early access for select plaintiffs firms.